Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors
Latest Information Update: 15 Sep 2023
At a glance
- Drugs Cabozantinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms CaPture
- 10 Mar 2022 Planned End Date changed from 7 Dec 2023 to 14 Dec 2024.
- 10 Mar 2022 Planned primary completion date changed from 7 Jun 2023 to 14 Jun 2024.
- 27 Apr 2021 Planned initiation date changed from 1 Apr 2021 to 29 Apr 2021.